Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new anticancer agent (LY186641) interferes with creatinine assay.

M M Bonnay1, G Recondo, A J Gouyette

  • 1Département de Biologie Clinique, Institut Gustave-Roussy, Villejuif,France.

Cancer Chemotherapy and Pharmacology
|January 1, 1989
PubMed
Summary

The anticancer drug LY186641 interferes with creatinine tests due to its metabolite. A new, interference-free method is proposed to ensure accurate patient monitoring during clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors.

ESMO open·2022
Same author

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Radionecrosis versus disease progression in brain metastasis. Value of (18)F-DOPA PET/CT/MRI.

Revista espanola de medicina nuclear e imagen molecular·2016
Same author

Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

European journal of cancer (Oxford, England : 1990)·2016
Same author

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors.

Investigational new drugs·2012
Same author

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.

Annals of oncology : official journal of the European Society for Medical Oncology·2011

Area of Science:

  • Pharmacology
  • Clinical Chemistry
  • Analytical Chemistry

Background:

  • Diarylsulfonylurea LY186641 is in Phase I clinical trials as an anticancer agent.
  • Common creatinine analysis methods are susceptible to analytical interference.

Purpose of the Study:

  • To identify the cause of analytical interference observed with LY186641 administration.
  • To develop and propose an alternative method for creatinine analysis that is free from interference.

Main Methods:

  • Investigated the interference of LY186641 with standard creatinine assays.
  • Characterized the interfering substance as a metabolite of LY186641.
  • Developed and validated a novel, interference-free analytical method.

Main Results:

Related Experiment Videos

  • Confirmed that a metabolite of LY186641, not the parent drug, causes significant interference.
  • The proposed alternative method successfully eliminates the analytical interference.

Conclusions:

  • The metabolite of LY186641 interferes with standard creatinine tests.
  • The newly developed method provides accurate creatinine measurements in the presence of LY186641 and its metabolites, crucial for clinical trial monitoring.